SEC Comment Letter for Harpoon Therapeutics, Inc. (CIK 0001708493) — Mar 19, 2020
Harpoon Therapeutics, Inc. (CIK 0001708493)
Date: March 19, 2020 · CIK: 0001708493 · Accession: 0000000000-20-002448
AI Filing Summary & Sentiment
File numbers found in text: 333-237175
Letter
March 19, 2020 Gerald McMahon, Ph.D. President and Chief Executive Officer Harpoon Therapeutics, Inc. 131 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 Re:Harpoon Therapeutics, Inc. Registration Statement on Form S-3 Filed March 13, 2020 File No. 333-237175 Dear Dr. McMahon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jonie Ing Kondracki - Cooley LLP
Show Raw Text
March 19, 2020
Gerald McMahon, Ph.D.
President and Chief Executive Officer
Harpoon Therapeutics, Inc.
131 Oyster Point Blvd, Suite 300
South San Francisco, California 94080
Re:Harpoon Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 13, 2020
File No. 333-237175
Dear Dr. McMahon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jonie Ing Kondracki - Cooley LLP